Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals's Climate Target Data Preview
As of 2024, Glenmark Pharmaceuticals has disclosed 2 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 1 absolute reduction target and 1 intensity-based target target, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into Glenmark Pharmaceuticals ’s climate strategy, ambition level, and alignment with global decarbonization goals.
| Target Type | Scope of Target | Unit | Target | Target Year |
|---|---|---|---|---|
Absolute-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2035 |
Intensity-based Target | Scope 3 - Purchased Goods and Services (Cat. 1), Scope 3 - Fuel- and Energy-Related Services (Cat. 3), Scope 3 - Downstream Transportation and Distribution (Cat. 9), Scope 3 - Investments (Cat. 15) | Metric Tonnes of CO2 equivalent (mtCO2e) per Metric Tonne (mt) of Unspecified Product from Unspecified Activities | Copy restricted. Please purchase to unlock this data.  | 2035 |
This table provides a simplified preview of selected climate targets data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Glenmark Pharmaceuticals's Greenhouse Gas Emissions Pathways
As of 2024, Glenmark Pharmaceuticals has set greenhouse gas (GHG) emissions reduction targets that cover both its operational emissions (Scope 1 and 2) and value chain emissions (Scope 3), offering a comprehensive view of its total carbon footprint.
Does Glenmark Pharmaceuticals have a target to reduce the emissions from its operations?
As of 2024, Glenmark Pharmaceuticals has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.
Glenmark Pharmaceuticals's most ambitious operational target is to reduce these emissions by 35% by 2035, compared to a baseline of 79,526 Metric Tonnes of CO2 equivalent (mtCO2e) in 2021.
Instead of reducing operational emissions, Glenmark Pharmaceuticals has increased them, with 2024 levels exceeding those of the 2021 baseline, placing the company well behind its reduction target.